8-KEarnings & Results

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Jan 9, 2018)

Filed January 9, 2018For Securities:BSX

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report on January 9, 2018, to announce preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2017. This filing serves as an early communication of key financial performance indicators before the official earnings release. Investors should note that these results are preliminary and subject to revision as the company completes its standard financial closing procedures. The company provided a cautionary statement regarding forward-looking statements, emphasizing that actual results could differ materially from expectations due to various risks and uncertainties. These include, but are not limited to, economic conditions, competitive pressures, new product introductions, market acceptance, reimbursement issues, and clinical trial outcomes. Investors are advised to consider these factors when evaluating the preliminary sales figures.

Key Highlights

  • 1Boston Scientific Corp (BSX) released preliminary unaudited sales results for Q4 and full-year 2017.
  • 2The information was provided via a press release dated January 9, 2018, attached as Exhibit 99.1.
  • 3The filed results are preliminary and subject to revision based on the company's standard financial closing processes.
  • 4The company included a standard cautionary statement regarding forward-looking statements.
  • 5Factors that could cause actual results to differ materially from preliminary estimates were outlined.
  • 6Risks and uncertainties include market conditions, product acceptance, regulatory environments, and competitive factors.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly share Boston Scientific Corporation's preliminary, unaudited sales results for the fourth quarter and the full fiscal year ended December 31, 2017, ahead of their formal earnings announcement.

No, the sales figures reported are preliminary and unaudited. The company states that actual results could differ materially as they complete their standard financial closing and review processes.

The company highlights several risks and uncertainties that could impact future results. These include future economic and political conditions, competitive and reimbursement pressures, the success of new product introductions and market acceptance, clinical trial results, and the overall execution of their business strategy.

The detailed preliminary sales figures are provided in the press release (Exhibit 99.1) attached to this 8-K filing. Investors should refer to that document for specific sales numbers.